Provided by Tiger Trade Technology Pte. Ltd.

Inhibikase Therapeutics, Inc.

1.64
-0.0650-3.82%
Volume:116.50K
Turnover:193.94K
Market Cap:197.84M
PE:-3.10
High:1.72
Open:1.72
Low:1.62
Close:1.70
52wk High:3.32
52wk Low:1.33
Shares:121.00M
Float Shares:71.11M
Volume Ratio:0.72
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5276
EPS(LYR):-0.3086
ROE:-131.71%
ROA:-79.11%
PB:2.71
PE(LYR):-5.30

Loading ...

BofA Securities Initiates Coverage on Inhibikase Therapeutics With Buy Rating, $6 Price Target

MT Newswires Live
·
Jan 21

Inhibikase Therapeutics Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $6

THOMSON REUTERS
·
Jan 21

Inhibikase Therapeutics Initiated at Buy by B of A Securities

Dow Jones
·
Jan 21

Inhibikase Therapeutics initiated with a Buy at BofA

TIPRANKS
·
Jan 21

Inhibikase Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
Dec 26, 2025

Inhibikase Therapeutics Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $8

THOMSON REUTERS
·
Dec 26, 2025

Inhibikase Therapeutics Inc - Files Prospectus Supplement for Atm Program - SEC Filing

THOMSON REUTERS
·
Dec 20, 2025

Inhibikase Therapeutics: Co May Offer & Sell Shares of Common Stock for up to $185 Mln From Time to Time

THOMSON REUTERS
·
Dec 20, 2025

Indonesia Launches First 48-Ton Frozen Durian Export to China

Tempo
·
Dec 15, 2025

Inhibikase Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Dec 11, 2025

Cantor Fitzgerald Initiates Inhibikase Therapeutics With Overweight Rating, $4 Price Target

MT Newswires Live
·
Dec 11, 2025

Inhibikase Therapeutics Reports Q3 2025 Financials and Progress

TIPRANKS
·
Nov 25, 2025

Sands Capital Life Sciences Pulse Fund II Reports Acquisition of Inhibikase Therapeutics Common Shares

Reuters
·
Nov 25, 2025

Inhibikase Therapeutics Announces $93.6 Million Stock Offering

TIPRANKS
·
Nov 22, 2025

Inhibikase Therapeutics Shares up 7.2% Premarket After Co Advances Experimental Pulmonary Arterial Hypertension Drug to Late-Stage Study

THOMSON REUTERS
·
Nov 21, 2025

Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45

TIPRANKS
·
Nov 21, 2025

BRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share

Reuters
·
Nov 21, 2025

Inhibikase Therapeutics Inc - Prices Public Offering of 46 Mln Shares at $1.45 per Share

THOMSON REUTERS
·
Nov 21, 2025

Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study

TIPRANKS
·
Nov 21, 2025

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
Nov 21, 2025